Citigroup
ISEE

Citigroup’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Citigroup’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-107,400
Closed -$4.23M – 5898
2023
Q2 		$4.23M Buy
+107,400
New +$3.79M ﹤0.01% 1606
2018
Q4 		– Sell
-900
Closed -$2K – 7883
2018
Q3 		$2K Buy
900
+600
+200% +$1.5K ﹤0.01% 7628
2018
Q2 		$1K Sell
300
-3,300
-92% -$9.1K ﹤0.01% 7562
2018
Q1 		$10K Sell
3,600
-200
-5% -$580 ﹤0.01% 7066
2017
Q4 		$12K Hold
3,800
– – ﹤0.01% 6972
2017
Q3 		$11K Buy
3,800
+3,200
+533% +$8.64K ﹤0.01% 6672
2017
Q2 		$2K Sell
600
-100
-14% -$272 ﹤0.01% 7048
2017
Q1 		$3K Sell
700
-79,100
-99% -$334K ﹤0.01% 6955
2016
Q4 		$385K Buy
79,800
+73,100
+1,091% +$2.17M ﹤0.01% 4656
2016
Q3 		$309K Buy
+6,700
New +$378K ﹤0.01% 4324

Citigroup's ISEE Position: Q3 2023 in Review

Citigroup sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 297,957 shares — an estimated $11.7M sold.

Citigroup first reported a position in ISEE in Q4 2013 and held it in 39 quarters. The position peaked at $11.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • Citigroup reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Citigroup sold 297,957 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $11.7M.
  • Citigroup first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 39 quarters.
  • Citigroup's IVERIC bio, Inc. Common Stock position peaked at $11.7M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.